U.S. health officials are expected to present data at an upcoming Centers for Disease Control and Prevention (CDC) advisory meeting that they say link COVID-19 vaccinations to a number of child deaths. The presentation, led by the U.S. Food and Drug Administration (FDA), is based on an analysis of adverse event reports submitted following COVID-19 immunization.
According to the FDA, the data being compiled include details of 25 pediatric deaths reported to the Vaccine Adverse Event Reporting System (VAERS). The reports involve children who died within a defined period after receiving a COVID-19 vaccine. Officials have emphasized that the presence of a report in VAERS does not establish a causal relationship.
VAERS accepts submissions from healthcare providers, patients, and the public, and serves as an early warning system for potential safety issues related to vaccines. The CDC’s Advisory Committee on Immunization Practices (ACIP) will review the FDA’s findings during its meeting scheduled for September 18 and 19. The data are being submitted as part of a broader agenda on immunization safety and policy updates.
ACIP is tasked with making recommendations on the use of vaccines in the U.S. civilian population and its meetings serve as a platform for reviewing scientific evidence surrounding vaccine safety and efficacy. FDA Commissioner Dr. Marty Makary confirmed that the agency is investigating the reported pediatric fatalities. He stated that a thorough review is underway to assess any potential link between the vaccines and the reported deaths, and that any presentation to the CDC will include only verified data.
COVID vaccine fatalities under official review
The agency has not publicly concluded that the vaccines caused the deaths. The reported cases span a range of clinical conditions and time frames, and are currently under individual medical review. Public health authorities have reiterated that such events are rare and must be evaluated against the overall rate of pediatric mortality and the incidence of COVID-19 in children.
Health agencies continue to monitor vaccine safety through multiple surveillance systems in addition to VAERS, including the Vaccine Safety Datalink and the Clinical Immunization Safety Assessment project. These systems allow for more rigorous, data-driven evaluations and are used to validate preliminary findings from VAERS reports. The CDC maintains that COVID-19 vaccines authorized for children have undergone extensive clinical trials and post-authorization monitoring.
The vaccines currently approved for pediatric use met safety and efficacy thresholds required under U.S. law. Previous reviews by federal health officials have not identified a statistically significant increase in mortality risk among vaccinated children. The ACIP meeting is being closely watched by medical professionals, policymakers, and advocacy groups.
Pediatric fatalities post-vaccine under investigation
The committee’s recommendations carry significant weight in shaping national immunization practices and are typically adopted by the CDC and other federal agencies. Any discussion involving child health and vaccine safety draws heightened attention due to its public health implications. More than 600 million COVID-19 vaccine doses have been administered in the United States, including millions to children.
Health authorities have reported that serious adverse events remain extremely rare. The FDA and CDC have consistently stated that the benefits of vaccination in preventing severe illness and hospitalization continue to outweigh the risks, particularly during periods of high community transmission. The upcoming meeting will include public comment sessions and is open for live viewing. – By Content Syndication Services.